Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.67 |
| ▸ | PGR | P06401 | 4/20 | 0.67 |
| ▸ | UBE2M | P61081 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595489 | 1.00 | AR (0.67) | ARPGRUBE2MDCUN1D1MLYCD | |
| SCHEMBL4897884 | 0.91 | AR (0.77) | ARPGRUBE2MDCUN1D1S1PR1 | |
| SCHEMBL4897879 | 0.91 | AR (0.77) | ARPGRUBE2MDCUN1D1S1PR1 | |
| SCHEMBL4595594 | 0.90 | AR (0.55) | ARPGRUBE2MDCUN1D1MLYCD | |
| SCHEMBL4906038 | 0.89 | AR (0.74) | ARPGRUBE2MDCUN1D1S1PR1 | |
| SCHEMBL4906033 | 0.89 | AR (0.74) | ARPGRUBE2MDCUN1D1S1PR1 | |
| SCHEMBL4906028 | 0.85 | AR (0.74) | ARPGRUBE2MDCUN1D1S1PR1 | |
| SCHEMBL14086485 | 0.85 | AR (0.74) | ARPGRUBE2MDCUN1D1S1PR1 | |
| SCHEMBL4903309 | 0.85 | AR (0.80) | ARPGRS1PR1 | |
| SCHEMBL4903315 | 0.85 | AR (0.80) | ARPGRS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | claimed |
| EP-1871379-A2 | CYANOARYLAMINES | Smithkline Beecham Corporation (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2006113552-A2 | CYANOARYLAMINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | claimed |
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | EDNRA, CYP19A1, HSD17B11 | AR 84/4885PGR 64/4885UBE2M 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.